louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05463276: The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
Official title: The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Breast Neoplasms
Breast Cancer Invasive
Breast Cancer Stage
Breast Cancer Metastatic
Keywords: Breast cancer
Clinical audit
Breast cancer risk factors
Breast cancer screening
Clinicopathological characterisitics
Lead sponsor: Sindh Institute of Urology and Transplantation
Sponsor class: OTHER
First posted: 2022-07-18
Enrollment: 690
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All breast cancer patients registered at the Breast Clinic, at the Sindh Institute of Urology and Transplantation (SIUT), Karachi from March 2017 till December 2021 were included

Brief summary: This cross-sectional study, conducted at the Sindh Institute of Urology and Transplantation (SIUT), involved a retrospective data review of all the patients diagnosed with breast cancer from March 2017 to December 2021. The demographic characteristics, clinical presentation, stage of the disease, and histopathological characteristics were analyzed.


Eligibility criteria: Inclusion Criteria:

* All patients diagnosed with breast cancer

Exclusion Criteria:

* The patients that were lost to follow-up after the first consultation and those consulting for a second opinion were excluded from the study.

Primary outcomes:
measure: Demographic characteristics of patients with breast cancer
timeFrame: At the time of presentation
measure: Risk factors of patients with breast cancer
timeFrame: At the time of presentation
measure: Clinical presentation of patients with breast cancer
timeFrame: At the time of presentation
measure: Stage of the breast cancer
timeFrame: At the time of presentation
measure: Histopathological characteristics of patients with breast cancer
timeFrame: At the time of presentation
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Sindh Institute of Urology and Transplantation
state: Sindh
Study officials:
affiliation: Sindh Institute of Urology and Transplantation
name: Murk Niaz
role: PRINCIPAL_INVESTIGATOR
affiliation: Sindh Institute of Urology and Transplantation
name: Bushra Shirazi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06917976: Evaluating the Effects of Psychological Stress on Salivary Biomarkers in Pediatric Patients Visiting Pediatric and General Dental Clinic
Official title: Evaluating the Effects of Psychological Stress on Salivary Biomarkers in Pediatric Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Salivary Cortisol
Salivary Alpha Amylase
Lead sponsor: Al-Mustansiriyah University
Sponsor class: OTHER
First posted: 2025-04-09
Enrollment: 80
Sex: MALE
Minimum age (years): 4
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: male children from 4-6 years old with first dental clinic

Brief summary: the goal of this study is to test the effect of psychological stress on pediatric patients visiting specialized and general dental clinic by measure salivary cortisol and salivary alpha amylase and by use children fear survey schedule -dental subscale .

80 male subjects will be enrolled in this study between 4-6 years old with first dental visit ,40 subjects visiting specialized pediatric dental clinic to see the effect of specific environment and attitude of dentist on child stress ,and 40 subjects visiting general dental clinic with normal environment and general dentist .

the method of study is by taking two saliva sample from child , first when he will enter the clinic at reception and second after half hour when he will diagnosed without any type of treatment.


Eligibility criteria: Inclusion Criteria:

* male
* 4-6 years old
* first dental visit
* patients with no systemic disease

Exclusion Criteria:

* medically compressed patient
* patients with systemic disease

Primary outcomes:
measure: salivary alpha amylase
timeFrame: Baseline: saliva collection for cortisol and salivary alpha amylase measurement. up to half hour :saliva collection will be performed again as described at base line visit.
measure: salivary cortisol
timeFrame: Baseline: saliva collection for cortisol and salivary alpha amylase measurement. up to half hour :saliva collection will be performed again as described at base line visit.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01639976: Doppler Flow Measurements in Patients With Misoprostol Treatment for Arrested Pregnancy
Official title: Testing the Connection Between the Existence of Endometrial Flows With Doppler Examination if the Treatment Cytotec Success in Women With Miss Abortion
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Missed Abortion
Keywords: Missed abortion, early pregnancy loss.
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-07-13
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with miss abortion who choose treatment with cytotec

Brief summary: Testing the whether Doppler studies after cytotec treatment can predict success of treatment.

Detailed description: All women who are treated with Cytotec for a missed abortion at 1st trimester will have a follow up ultrasound exam.

Doppler measurements will be performed but will be hidden from the clinicians. After the conclusion of treatment, data on Doppler would be vevealed in order to see if positive Doppler after Cytotec is predictive of failure of treatment or the need in several doses of cytotec.

Eligibility criteria: Inclusion Criteria:

* Women with miss abortion who choose treatment with cytotec

Exclusion Criteria:

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Alon Shrim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02366676: Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
Official title: Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract: a Multicenter, Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Recurrent Cystitis
Keywords: Recurrent cystitis
hyaluronic acid
chondroitin sulphate
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2015-02-19
Enrollment: 105
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract

Detailed description: The purpose of this study is to evaluate the efficacy of combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IARULIL®) in the treatment of recurrent cystitis refractory to oral Escherichia Coli extract(Uro-Vaxom®) and the change of urinary tract infection symptoms after intravesical instillation treatment with IARULIL®.

Eligibility criteria: Inclusion Criteria:

1. female patients aged between 20 and 80 years
2. Patients diagnosed with recurrent cystitis and treated with Escherichia Coli Extract
3. Patients with Refractory to Escherichia Coli Extract treatment

Exclusion Criteria:

1. child-bearing potential, pregnant or nursing women.
2. Residual urine volume \>100ml
3. genitourinary tuberculosis or cancer / anatomical abnomality of genitourinary tract / neurologic abnormality of low urinary tract.
4. history of treatment for acute cystitis within 2weeks.

Primary outcomes:
measure: The number of recurrence for recurrent cystitis
timeFrame: 12 months
Secondary outcomes:
measure: Time interval of cystitis
timeFrame: 12months
measure: The score change of UTI symptom Assessment questionnaire(UTISA)
timeFrame: 12months
measure: Global Respone assessment(GRA) score assessment
timeFrame: 12 month after treatment
measure: safety evaluation Safety evaluation
timeFrame: 12 month after treatment
Other outcomes:
Locations:
city: Seoul,
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Kyu-Sung Lee, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06811376: Pilot Trial of Spiritual Care Interventions for Patients With Cancer
Official title: Pilot Trial of Spiritual Care Interventions for Patients With Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Advanced Cancer
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
Collaborators: name: New York Presbyterian Brooklyn Methodist Hospital
name: The University of Texas Medical Branch, Galveston
name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2025-02-06
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a pilot trial of the effects of spiritual care interventions on spiritual well-being and readiness to engage in advance care planning (ACP) among black patients with advanced cancer recruited from outpatient settings to determine the feasibility of conducting a larger trial of effects of early integration of spiritual care into outpatient oncology care on patient outcomes.

Detailed description: This will be a pilot, stratified block randomized controlled trial of the effects of healthcare chaplain services on spiritual well-being and advance care planning (ACP) among black advanced cancer patients (N=64) in outpatient settings at two medical institutions: NYP/Brooklyn Methodist Hospital (BMH) and the University of Texas Medical Branch (UTMB). The investigators will randomly assign patients in a 1:1 ratio to either the Spiritual Care Intervention #1 or Spiritual Care Intervention #2 arm of the trial. Intervention details are being withheld until the trial concludes to protect the scientific integrity of the study. Trial outcomes will be assessed at the primary endpoint, 2 months after the onset of the spiritual care intervention.

Eligibility criteria: Inclusion Criteria:

1. Diagnosed with a life-limiting, advanced cancer.
2. Identifies racially as black or African American.
3. Is fluent in English.

Exclusion Criteria:

1. Have received medical system-based spiritual care within the past 2 months.
2. Have already completed a DNR order.
3. Are too weak or cognitively impaired to engage in study activities

Primary outcomes:
measure: Measure of Spiritual Well-Being as assessed by Functional Assessment of Chronic Illness Therapy--Spiritual Well-Being Scale [FACIT-Sp].
timeFrame: 2 months
measure: Readiness to Engage in Advance Care Planning as assessed by the Advance Care Planning Engagement Survey.
timeFrame: 2 months
Secondary outcomes:
measure: Number of individual participants who complete a DNR order.
timeFrame: 2 months
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: New York Presbyterian Brooklyn Methodist Hospital
state: New York
city: Galveston
country: United States
facility: The University of Texas Medical Branch, Galveston
state: Texas
Study officials:
affiliation: Weill Medical College of Cornell University
name: Paul K Maciejewski, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06076876: Prevalence and Risk Factors of Anxiety and Depression Among Policemen During the Health Crisis Linked to COVID-19
Official title: Prevalence and Risk Factors of Anxiety and Depression in Two Populations of Policemen During the Health Crisis Linked to COVID-19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Anxiety Syndrome
Depression Syndrome
Policemen
Keywords: Covid-19
Anxiety Syndrome
Depression Syndrome
Covid crisis
Police officers
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-10-11
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: National police officer in office in June 2020 in the departments of Bas Rhin and Hérault.

Brief summary: To date, there is little international data on depression and anxiety among police officers apart from studies carried out after an attack or natural disaster. At the national level, no mental health data exists for police officers, apart from those from the Paris attacks, and the work of investigators after the Strasbourg attack (article in press).

During the covid crisis, in Alsace, the police, like the rest of the population, took the full brunt of the pandemic. The police, however, are part of essential professions and have not been confined, but on the contrary, have remained in contact with the population, in particular to carry out traffic controls. Studies published to date show varying mental health outcomes for essential occupations during the pandemic.

The investigators hypothesize that the police officers had a feeling of being more exposed and that their mental health could be affected. For this it was decided to compare two populations of departments of similar size, but with different exposure to the pandemic: Bas Rhin and Hérault French departments


Eligibility criteria: Inclusion Criteria:

* Any major agent in office in June 2020 of the national police of the Bas Rhin department, and Hérault
* Supported between June and September 2020
* Subject not opposing, after information, the reuse of their data for the purposes of this research

Exclusion Criteria:

* Subject having expressed his opposition to his data being reused for study purposes

Primary outcomes:
measure: Prevalence of depression and anxiety among policemen from two regions differently exposed to COVID 19
timeFrame: 6 months after the covid crisis
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Pathologie Professionnelle - Médecine du Travail - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT01066676: Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee
Official title: Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteoarthritis of the Hip or Knee
Lead sponsor: Gebro Pharma GmbH
Sponsor class: INDUSTRY
First posted: 2010-02-10
Enrollment: 482
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Medical condition under investigation: Osteoarthritis of the hip or knee

Number of patients planned: 480 adult patients

Main objective: To evaluate and compare the tolerability profile of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients with painful osteoarthritis of the hip or knee

Secondary objectives: To compare the overall efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients suffering from different complaints due to painful osteoarthritis of the hip or knee


Eligibility criteria: Inclusion Criteria:

* male or female patients aged between 18 and 75 years
* everyday joint pain for the past three months
* global pain intensity in the involved joint (hip or knee) of "moderate" to "severe" within the last 48 h

Exclusion Criteria:

* acute inflammation or ischaemic necrosis
* paget's disease, chondrocalcinosis, ochronosis of the hip/knee joint
* slowly progressing hip/knee arthropathy in particular of tuberculosis aetiology
* hip/knee arthropathy due to diabetes mellitus
* Charcot's joint
* villous synovitis
* chondromatosis of the synovium
* patients with existing gastritis or existing ulcers or bleedings in the gastrointestinal tract or patients with history of gastrointestinal ulcers or gastrointestinal haemorrhage in the past 6 months

Primary outcomes:
measure: Tolerability profile of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients with painful osteoarthritis of the hip or knee
timeFrame: 14 days
Secondary outcomes:
measure: Overall efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients suffering from different complaints due to painful osteoarthritis of the hip or knee
timeFrame: 14 days
Other outcomes:
Locations:
city: Bad Hofgastein
country: Austria
facility: Rehabzentrum für Erkrankungen des rheumat. Formenkreises
state: Salzburg
city: Vienna
country: Austria
facility: Rheuma Zentrum Favoriten
Study officials:
affiliation: Rehabilitationszentrum, Bad Hofgastein
name: Reinhold Hawel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02603276: Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination
Official title: Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination in Moderately Hypercholesterolemic Subjects in Primary Prevention for Cardiovascular Diseases: a Randomized, Double Blind, Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypercholesterolemia
Keywords: hypercholesterolemia
dietary supplements
red yeast rice
plant sterols
Lead sponsor: University of Bologna
Sponsor class: OTHER
First posted: 2015-11-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A large body of evidence confirm the cholesterol lowering effect of phytosterols and red yeast rice. Because their mechanisms of action mime the ones of chemical statins and cholesterol absorption inhibitors, it is plausible that their association will provide a more relevant (and safe) LDL cholesterolemia reduction.

Detailed description: A large body of literature suggest that the patients are strongly interested in self-medicating them with "natural" products aimed at reducing their plasma level of LDL-cholesterol. Plant sterols and red yeast rice are among the most widely marketed product with these properties in Western countries. However plant sterols per se have a limited effect on cholesterolemia, while full dosed red yeast rice can induce myalgias and myopathies as statins do. In this context, the aim of the investigators' study was to evaluate if the association of both products at low dosage could induce an additive or synergistic effect in term of LDL-reduction in humans.

Eligibility criteria: Inclusion Criteria:

* LDL-cholesterolemia between 130 and 190 mg/dL

Exclusion Criteria:

* Type 2 diabetes
* Previous cardiovascular disease
* Assumption of lipid-lowering drugs or dietary supplements
* Previous intolerance to red yeast rice

Primary outcomes:
measure: LDL cholesterolemia reduction from baseline and between groups
timeFrame: 8 weeks
Secondary outcomes:
measure: Non-HDL cholesterolemia reduction from baseline and between groups
timeFrame: 8 weeks
measure: Number of Participants With Treatment-Related Adverse Events
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: S. Orsola-Malpighi University Hospital
Study officials:
affiliation: University of Bologna
name: Claudio Borghi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cicero AFG, Fogacci F, Rosticci M, Parini A, Giovannini M, Veronesi M, D'Addato S, Borghi C. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab (Lond). 2017 Sep 25;14:61. doi: 10.1186/s12986-017-0214-2. eCollection 2017.
Clinical trial NCT00194376: Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea
Official title: Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastroesophageal Reflux
Sleep Apnea
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Patients with a clinically indicated sleep study will be enrolled in this study. They will have a diagnostic and a therapeutic sleep study with continuous positive airway pressure ventilation. For both studies a pH probe will be placed nasal to measure the amount of acidic reflux during each study. Baseline levels of reflux from the diagnostic sleep study will be compared to reflux episodes while on continuous positive airway pressure ventilation.


Eligibility criteria: Inclusion Criteria:

* 18-75 years of age, symptoms consistent with sleep apnea, agree to consent form and placement of pH probes

Exclusion Criteria:

* any unstable medical condition, previous upper gi surgery or anatomic abnormality of upper gi tract, acid suppressing medication

Primary outcomes:
measure: Decrease in GERD symptoms
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: David Metz, MD
role: PRINCIPAL_INVESTIGATOR
References: